MX337161B - Process for the manufacture of a vaccine reagent of erythrocytes parasitized by babesia bovis or babesia bigemina. - Google Patents

Process for the manufacture of a vaccine reagent of erythrocytes parasitized by babesia bovis or babesia bigemina.

Info

Publication number
MX337161B
MX337161B MX2012000670A MX2012000670A MX337161B MX 337161 B MX337161 B MX 337161B MX 2012000670 A MX2012000670 A MX 2012000670A MX 2012000670 A MX2012000670 A MX 2012000670A MX 337161 B MX337161 B MX 337161B
Authority
MX
Mexico
Prior art keywords
babesia
vaccine
reagent
manufacture
vaccine reagent
Prior art date
Application number
MX2012000670A
Other languages
Spanish (es)
Other versions
MX2012000670A (en
Inventor
Julio Vicente Figueroa Millan
Jesús Antonio Alvarez Martinez
Carmen Rojas Martinez
Original Assignee
Inst Nac De Investigaciones Forestales Agricolas Y Pecuarias
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47225245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX337161(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nac De Investigaciones Forestales Agricolas Y Pecuarias filed Critical Inst Nac De Investigaciones Forestales Agricolas Y Pecuarias
Priority to MX2012000670A priority Critical patent/MX337161B/en
Publication of MX2012000670A publication Critical patent/MX2012000670A/en
Publication of MX337161B publication Critical patent/MX337161B/en

Links

Abstract

Provided is a method for the manufacture of a live attenuated bivalent vaccine reagent of Babesia bovis and Babesia bigemina which increases in at least 300% the production of the vaccine reagent (parasitized erythrocytes), which reduces in a substantial manner the time required for producing the batch vaccine, also reducing in a 90% the volume of the vaccine reagent (parasitized erythrocytes) by vaccine dose, and optimising the storage space. Additionally, the present invention recovers the Babesia proteins from the supernatant, which are also used as immunogens against the babesiosis and as antigens for diagnosis tests. The vaccine reagent obtained by the present invention has been assessed in laboratory tests and field tests, showing safety and effectiveness in cattle.
MX2012000670A 2012-01-13 2012-01-13 Process for the manufacture of a vaccine reagent of erythrocytes parasitized by babesia bovis or babesia bigemina. MX337161B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2012000670A MX337161B (en) 2012-01-13 2012-01-13 Process for the manufacture of a vaccine reagent of erythrocytes parasitized by babesia bovis or babesia bigemina.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2012000670A MX337161B (en) 2012-01-13 2012-01-13 Process for the manufacture of a vaccine reagent of erythrocytes parasitized by babesia bovis or babesia bigemina.

Publications (2)

Publication Number Publication Date
MX2012000670A MX2012000670A (en) 2012-08-31
MX337161B true MX337161B (en) 2016-02-12

Family

ID=47225245

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000670A MX337161B (en) 2012-01-13 2012-01-13 Process for the manufacture of a vaccine reagent of erythrocytes parasitized by babesia bovis or babesia bigemina.

Country Status (1)

Country Link
MX (1) MX337161B (en)

Also Published As

Publication number Publication date
MX2012000670A (en) 2012-08-31

Similar Documents

Publication Publication Date Title
EA201591131A1 (en) DNA STRUCTURE ANTIBODY AND METHOD OF THEIR APPLICATION
MX2018007022A (en) Methods for treatng huntington's disease.
MX2013001613A (en) Methods and compositions for preventing a condition.
MY171038A (en) Bispecific antigen binding molecules
EA201400625A1 (en) ANTIBODIES AGAINST PD-L1 AND THEIR APPLICATION
MX2022008523A (en) Glycan-interacting compounds and methods of use.
BR112015012933A2 (en) bcma antigen binding proteins
MX2015000863A (en) Anti-siglec-15 antibodies.
MX344673B (en) Apparatus and method for isolating leukocytes and tumor cells by filtration.
BR112017010793A2 (en) genetically modified nonhuman animal, mouse, methods for producing a genetically modified nonhuman animal and screening for drug candidates directed to an antigen of interest, and, mouse model.
MX2014009628A (en) Cdim binding proteins and uses thereof.
MX359854B (en) Anti-cxcr3 antibodies.
EA201591791A1 (en) MAN PAC1 ANTIBODIES
PH12020550169A1 (en) Isothiocyanate containing brassicaceae products and method of preparation thereof
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
NZ717399A (en) Antibodies against csf-1r
MX2022006304A (en) Compositions and methods for inhibiting the biological activity of soluble biomolecules.
UA105073C2 (en) Anti-fractalkine antibody, composition and method for treating inflammatory disorders
GB201017519D0 (en) Vaccines
WO2010045573A3 (en) Tumor vaccine
MX2022000242A (en) Antibodies to ticagrelor and methods of use.
TR201910413T4 (en) Methods for improving asthma symptoms using benralizumab.
BR112016006383A2 (en) protein extraction method
NZ724772A (en) Antibodies against hpa-1a
SG10201903424RA (en) ANTI HUMAN Gas6 MONOCLONAL ANTIBODY

Legal Events

Date Code Title Description
FG Grant or registration